India, Aug. 25 -- Eris Lifesciences Ltd, a leading Indian branded formulations company, announced that one of its manufacturing units at the Ahmedabad campus has received approval from ANVISA, Brazil's national health regulator.

The approval, which follows a successful inspection in May 2025, will allow Eris to enter Brazil — the largest pharmaceutical market in South America.

A company spokesperson said the clearance from a stringent authority like ANVISA is a strong validation of Eris's GMP compliance and robust quality systems. The Ahmedabad facility has also cleared inspections by several other regulatory bodies earlier this year.

Published by HT Digital Content Services with permission from Dion Global Solutions Limited....